8-K: HCW Biologics Secures $6.9 Million in Direct Offering and Private Placement, Licenses Preclinical Candidate for $7 Million Upfront

HCW Biologics has raised approximately $6.9 million through a registered direct offering and concurrent private placement, while also licensing a preclinical immunotherapeutic candidate to WY Biotech for a $7 million upfront payment.

Summary

• HCW Biologics entered into a securities purchase agreement on November 18, 2024, to sell 4,160,000 shares of common stock and pre-funded warrants for 2,557,000 shares in a registered direct offering.
• The company also conducted a concurrent private placement of unregistered warrants to purchase up to 6,717,000 shares of common stock.
• The combined purchase price was $1.03 per share and $1.0299 per pre-funded warrant, each including an accompanying common stock warrant.
• The common stock warrants have an exercise price of $1.03 per share, are exercisable immediately, and expire in five years.
• The pre-funded warrants have an exercise price of $0.0001, are exercisable immediately, and do not expire until fully exercised.
• The gross proceeds from the offering are approximately $6.9 million before deducting placement agent fees and other expenses.
• The offering closed on November 20, 2024.
• HCW Biologics also entered into a worldwide exclusive license agreement with WY Biotech for a preclinical immunotherapeutic candidate, receiving a $7 million upfront payment, potential milestone payments, and double-digit royalties on future sales.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with successful fundraising and a significant licensing agreement. The above-market pricing of the offering and the potential for future revenue streams from the licensing agreement contribute to a strong positive sentiment.

Positives

• The company successfully raised $6.9 million in gross proceeds, strengthening its financial position.
• The licensing agreement with WY Biotech provides a $7 million upfront payment and potential future revenue streams.
• The pre-funded warrants allow for immediate exercise at a nominal price, potentially increasing the number of shares outstanding.
• The company has secured a strategic partnership with WY Biotech for the development and commercialization of a promising immunotherapeutic candidate.
• The offering was priced above market under NASDAQ rules.

Negatives

• The offering includes warrants that could dilute existing shareholders if exercised.
• The company will incur placement agent fees and other offering expenses, reducing the net proceeds.
• The company is relying on a single institutional investor for the offering.

Risks

• The company's ability to achieve future milestone payments and royalties from the WY Biotech agreement is dependent on the successful development and commercialization of the licensed product.
• The company's future financial performance is dependent on the success of its drug development programs.
• The company may need to raise additional capital in the future to fund its operations.
• The company is subject to the risks associated with the biopharmaceutical industry, including clinical trial failures and regulatory hurdles.

Future Outlook

The company anticipates using the proceeds from the offering for working capital purposes and will collaborate with WY Biotech on the clinical and commercial development of the licensed immunotherapeutic candidate. The company also has an option to recapture the development and commercialization rights for the US, Canada, Central America and South America after the conclusion of the Phase 1 clinical trial.

Management Comments

• Dr. Hing C. Wong, HCWB's Founder and CEO, stated that the company has leveraged its knowledge of T cell and natural killer (NK) cell immunology and its new drug discovery platform technologies to develop a portfolio of potent immunotherapeutics.
• Dr. Wong also mentioned that the product candidate subject to the license with WY Biotech is highly effective at inducing anti-tumor CD8+ T cell and NK cell responses without triggering unwanted side effects in relevant solid tumor animal models.

Industry Context

This announcement reflects a trend in the biopharmaceutical industry where companies are seeking funding through direct offerings and private placements, while also leveraging strategic partnerships to advance their drug development programs. The licensing agreement with WY Biotech highlights the growing interest in immunotherapies and the potential for collaboration between US and Chinese biotech companies.

Comparison to Industry Standards

• The combined offering price of $1.03 per share and warrant is above market, which is a positive sign for the company's valuation.
• The $7 million upfront payment for the license agreement is a significant amount for a preclinical candidate, indicating the potential value of the molecule.
• The structure of the offering, including pre-funded warrants and common stock warrants, is a common practice in the biotech industry to attract investors.
• The double-digit royalties on future product sales are in line with industry standards for licensing agreements.
• The option for HCW Biologics to recapture rights in the US, Canada, Central America and South America is a common clause in licensing agreements to protect the company's future interests.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• The company's employees may benefit from the increased financial stability and potential for future growth.
• Customers may benefit from the development of new immunotherapeutic treatments.
• Suppliers and creditors may benefit from the company's improved financial position.

Next Steps

• The company will use the proceeds from the offering for working capital.
• HCW Biologics will collaborate with WY Biotech on the clinical and commercial development of the licensed immunotherapeutic candidate.
• The company will seek to maintain the listing of its common stock on the NASDAQ.

Key Dates

Keywords

HCW Biologics, immunotherapy, biopharmaceutical, registered direct offering, private placement, pre-funded warrants, common stock warrants, licensing agreement, WY Biotech, capital raise